1. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients
by Laurent Arnaud, Baptiste Hervier, Antoine Néel, Mohamed A. Hamidou, Jean-Emmanuel Kahn, Bertrand Wechsler, Gemma Pérez-Pastor, Bjørn Blomberg, Jean-Gabriel Fuzibet, François Dubourguet, António Marinho, Catherine Magnette, Violaine Noel, Michel Pavic, Jochen Casper, Anne-Bérangère Beucher, Nathalie Costedoat-Chalumeau, Laurent Aaron, Juan Salvatierra, Carlos Graux, Patrice Cacoub, Véronique Delcey, Claudia Dechant, Pascal Bindi, Christiane Herbaut, Giorgio Graziani, Zahir Amoura, and Julien Haroche
Blood
Volume 117(10):
March 10, 2011
©2011 by American Society of Hematology

2. Kaplan-Meier survival estimates of the survival function for the patients with ECD treated with (n = 27) or without (n = 26) involvement of the CNS. Hash marks indicate censored persons.
Kaplan-Meier survival estimates of the survival function for the patients with ECD treated with (n = 27) or without (n = 26) involvement of the CNS. Hash marks indicate censored persons.
Laurent Arnaud et al. Blood 2011;117:
©2011 by American Society of Hematology

3. Kaplan-Meier survival estimates of the survival function for the patients with ECD treated with (n = 46) or without (n = 7) interferon-α and/or PEGylated interferon-α.
Kaplan-Meier survival estimates of the survival function for the patients with ECD treated with (n = 46) or without (n = 7) interferon-α and/or PEGylated interferon-α. Comparison of patients treated with and without interferon-α and/or PEGylated interferon-α shows a significant difference in survival between those 2 groups (log-rank test, P = .004). Hash marks indicate censored persons.
Laurent Arnaud et al. Blood 2011;117:
©2011 by American Society of Hematology